|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM22867574X |
| 003 |
DE-627 |
| 005 |
20231224080451.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2013 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2013.05.018
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0762.xml
|
| 035 |
|
|
|a (DE-627)NLM22867574X
|
| 035 |
|
|
|a (NLM)23803322
|
| 035 |
|
|
|a (PII)S1521-6616(13)00167-8
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Brooks-Worrell, Barbara
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Prevention versus intervention of type 1 diabetes
|
| 264 |
|
1 |
|c 2013
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.12.2013
|
| 500 |
|
|
|a Date Revised 16.11.2017
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2013 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Type 1 diabetes (T1D) is a cell-mediated autoimmune disease. New cases of T1D are on the increase and exogenous insulin therapy is the only intervention regularly initiated for T1D patients. Though tremendous strides have been made in prediction of T1D, prevention and intervention strategies have not experienced the same success. In this review, we will discuss some possible reasons why new intervention therapies for T1D have not been implemented into the mainstream treatment regimen for T1D patients. We will also discuss potential caveats for why prevention and intervention trials in T1D may not have experienced the same success as prediction trials
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Intervention
|
| 650 |
|
4 |
|a Islet autoimmunity
|
| 650 |
|
4 |
|a Prediction
|
| 650 |
|
4 |
|a Prevention
|
| 650 |
|
4 |
|a Type 1 diabetes
|
| 650 |
|
4 |
|a Type 2 diabetes
|
| 650 |
|
7 |
|a Antibodies, Monoclonal, Humanized
|2 NLM
|
| 650 |
|
7 |
|a CD3 Complex
|2 NLM
|
| 650 |
|
7 |
|a Hypoglycemic Agents
|2 NLM
|
| 650 |
|
7 |
|a Immunoconjugates
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
| 650 |
|
7 |
|a Insulin
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Tumor Necrosis Factor
|2 NLM
|
| 650 |
|
7 |
|a Abatacept
|2 NLM
|
| 650 |
|
7 |
|a 7D0YB67S97
|2 NLM
|
| 650 |
|
7 |
|a Glutamate Decarboxylase
|2 NLM
|
| 650 |
|
7 |
|a EC 4.1.1.15
|2 NLM
|
| 650 |
|
7 |
|a Etanercept
|2 NLM
|
| 650 |
|
7 |
|a OP401G7OJC
|2 NLM
|
| 650 |
|
7 |
|a teplizumab
|2 NLM
|
| 650 |
|
7 |
|a S4M959U2IJ
|2 NLM
|
| 700 |
1 |
|
|a Palmer, Jerry P
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 149(2013), 3 vom: 23. Dez., Seite 332-8
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:149
|g year:2013
|g number:3
|g day:23
|g month:12
|g pages:332-8
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2013.05.018
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 149
|j 2013
|e 3
|b 23
|c 12
|h 332-8
|